GlassScriptPhysician profile
Sivashankar Sivaraman
NPI 1922259514
$7,149.52
in general payments reported to CMS, 2019-2025
32 companies · $1,813 in 2025
The $1,813 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $531 · 2020: $345 · 2021: $579 · 2022: $953 · 2023: $1,123 · 2024: $1,807 · 2025: $1,813.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,589 · Education: $153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,589.32 |
| Education | $152.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,517.19 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,423.80 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Mylan Specialty L.P. | $585.98 | 2019-2024 | Yupelri |
| Genzyme Corporation | $539.97 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $425.52 | 2019-2025 | Ofev |
| Actelion Pharmaceuticals US, INC. | $283.79 | 2019-2025 | Opsumit, Uptravi |
| Philips North America LLC | $281.97 | 2019-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Jazz Pharmaceuticals INC. | $257.06 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $256.53 | 2019-2025 | Dupixent |
| Insmed, INC. | $190.89 | 2019-2025 | Arikayce |
| Viatris Specialty LLC | $153.56 | 2025 | Yupelri |
| Genentech USA, INC. | $148.46 | 2019-2024 | Xolair |
| Amgen INC. | $136.94 | 2022-2025 | Tezspire |
| Harmony Biosciences LLC | $122.52 | 2021-2025 | Wakix |
| Pulmonx Corporation | $112.75 | 2024 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $110.39 | 2025 | Ohtuvayre |
| Sanofi-Aventis U.S. LLC | $88.99 | 2024 | |
| Merck Sharp & Dohme LLC | $60.17 | 2020-2024 | Winrevair |
| Ani Pharmaceuticals, INC. | $53.10 | 2023-2024 | Purified Cortrophin Gel |
| United Therapeutics Corporation | $52.24 | 2024-2025 | Tyvaso, Tyvaso |
| Electromed, INC. | $49.60 | 2022-2023 | Smartvest |
| Bayer Healthcare Pharmaceuticals INC. | $45.25 | 2023 | |
| Grifols USA, LLC | $35.06 | 2025 | Prolastin-C Liquid |
| Takeda Pharmaceuticals U.S.A., INC. | $34.61 | 2020-2024 | Aralast |
| Avadel Cns Pharmaceuticals, LLC | $32.20 | 2024 | Lumryz |
| Axsome Therapeutics, INC. | $30.78 | 2023-2025 | Sunosi |
| Novartis Pharmaceuticals Corporation | $25.14 | 2023 | |
| Allergan, INC. | $25.00 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $22.59 | 2019 | |
| Baxter Healthcare | $22.26 | 2025 | |
| Portola Pharmaceuticals, LLC | $13.43 | 2020 | |
| Sunovion Pharmaceuticals INC. | $11.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sivashankar Sivaraman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.